Search

Your search keyword '"Matrone, Fabio"' showing total 13 results
Start Over Author "Matrone, Fabio" Search Limiters Full Text
13 results on '"Matrone, Fabio"'

1. Navigating the evolving diagnostic and therapeutic landscape of low- and intermediate-risk prostate cancer.

Author

Zattoni, Fabio, Matrone, Fabio, Bortolus, Roberto, and Giannarini, Gianluca

Abstract

In this nonsystematic review of the literature, we explored the changing landscape of detection and treatment of low- and intermediate-risk prostate cancer (PCa). Through emphasizing improved cancer assessment with histology classification and genomics, we investigated key developments in PCa detection and risk stratification. The pivotal role of prostate magnetic resonance imaging (MRI) in the novel diagnostic pathway is examined, alongside the benefits and drawbacks of MRI-targeted biopsies for detection and tumor characterization. We also delved into treatment options, particularly active surveillance for intermediate-risk PCa. Outcomes are compared between intermediate- and low-risk patients, offering insights into tailored management. Surgical techniques, including Retzius-sparing surgery, precision prostatectomy, and partial prostatectomy for anterior cancer, are appraised. Each technique has the potential to enhance outcomes and minimize complications. Advancements in technology and radiobiology, including computed tomography (CT)/MRI imaging and positron emission tomography (PET) fusion, allow for precise dose adjustment and daily target monitoring with imaging-guided radiotherapy, opening new ways of tailoring patients' treatments. Finally, experimental therapeutic approaches such as focal therapy open new treatment frontiers, although they create new needs in tumor identification and tracking during and after the procedure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Clinical Use of a Commercial Artificial Intelligence-Based Software for Autocontouring in Radiation Therapy: Geometric Performance and Dosimetric Impact

Author

Hoque, S M Hasibul, primary, Pirrone, Giovanni, additional, Matrone, Fabio, additional, Donofrio, Alessandra, additional, Fanetti, Giuseppe, additional, Caroli, Angela, additional, Rista, Rahnuma Shahrin, additional, Bortolus, Roberto, additional, Avanzo, Michele, additional, Drigo, Annalisa, additional, and Chiovati, Paola, additional

Published
2023
Full Text
View/download PDF

3. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients

Author

Macchia, Gabriella, Gambacorta, Maria Antonietta, Masciocchi, Carlotta, Chiloiro, Giuditta, Mantello, Giovanna, di Benedetto, Maika, Lupattelli, Marco, Palazzari, Elisa, Belgioia, Liliana, Bacigalupo, Almalina, Sainato, Aldo, Montrone, Sabrina, Turri, Lucia, Caroli, Angela, De Paoli, Antonino, Matrone, Fabio, Capirci, Carlo, Montesi, Giampaolo, Niespolo, Rita Marina, Osti, Mattia Falchetto, Caravatta, Luciana, Galardi, Alessandra, Genovesi, Domenico, Rosetto, Maria Elena, Boso, Caterina, Sciacero, Piera, Giaccherini, Lucia, Parisi, Salvatore, Fontana, Antonella, Filippone, Francesco Romeo, Picardi, Vincenzo, Morganti, Alessio Giuseppe, and Valentini, Vincenzo

Published
2017
Full Text
View/download PDF

4. Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects

Author

Brisotto, Giulia, primary, Montico, Marcella, additional, Turetta, Matteo, additional, Zanussi, Stefania, additional, Cozzi, Maria Rita, additional, Vettori, Roberto, additional, Boschian Boschin, Romina, additional, Vinante, Lorenzo, additional, Matrone, Fabio, additional, Revelant, Alberto, additional, Palazzari, Elisa, additional, Innocente, Roberto, additional, Fanetti, Giuseppe, additional, Gerratana, Lorenzo, additional, Garutti, Mattia, additional, Lisanti, Camilla, additional, Bolzonello, Silvia, additional, Nicoloso, Milena Sabrina, additional, Steffan, Agostino, additional, and Muraro, Elena, additional

Published
2023
Full Text
View/download PDF

6. Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients

Author

Lucchini, Elisa, primary, Rusconi, Chiara, additional, Levis, Mario, additional, Ricci, Francesca, additional, Santoro, Armando, additional, Ricardi, Umberto, additional, Volpetti, Stefano, additional, Matrone, Fabio, additional, di Russo, Anna, additional, Caizzi, Manuela, additional, Schiattarella, Anna, additional, and Zaja, Francesco, additional

Published
2021
Full Text
View/download PDF

7. Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy

Author

Fanetti, Giuseppe, primary, Polesel, Jerry, additional, Fratta, Elisabetta, additional, Muraro, Elena, additional, Lupato, Valentina, additional, Alfieri, Salvatore, additional, Gobitti, Carlo, additional, Minatel, Emilio, additional, Matrone, Fabio, additional, Caroli, Angela, additional, Revelant, Alberto, additional, Lionello, Marco, additional, Zammattio Polentin, Viviana, additional, Ferretti, Andrea, additional, Guerrieri, Roberto, additional, Chiovati, Paola, additional, Bertolin, Andy, additional, Giacomarra, Vittorio, additional, Paoli, Antonino De, additional, Vaccher, Emanuela, additional, Sartor, Giovanna, additional, Steffan, Agostino, additional, and Franchin, Giovanni, additional

Published
2021
Full Text
View/download PDF

8. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: Short-term results of a multicentric study

Author

Lupattelli, Marco, Matrone, Fabio, Gambacorta, Maria Antonietta, Osti, Mattia, Macchia, Gabriella, Palazzari, Elisa, Nicosia, Luca, Navarria, Federico, Chiloiro, Giuditta, Valentini, Vincenzo, Aristei, Cynthia, Paoli, Antonino, Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Lupattelli, Marco, Matrone, Fabio, Gambacorta, Maria Antonietta, Osti, Mattia, Macchia, Gabriella, Palazzari, Elisa, Nicosia, Luca, Navarria, Federico, Chiloiro, Giuditta, Valentini, Vincenzo, Aristei, Cynthia, Paoli, Antonino, Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)

Abstract

Background: Preoperative radiotherapy (RT) in combination with fluoropyrimidine-based chemotherapy (CT) is the standard of care in patients with locally advanced, T3-T4 N0-2, rectal cancer (LARC). Given the correlation between RT dose-tumor response and the prognostic role of the tumor regression grade (TRG), treatment intensification represents an area of active investigation. The aim of the study was to analyze the role of RT dose-intensification in the preoperative treatment of LARC in terms of feasibility, efficacy and toxicity. Methods: We retrospectively analyzed patients with LARC treated with intensity-modulated radiotherapy (IMRT) and simultaneous integrated boost (SIB) at five Italian radiation oncology centers. Concurrent Capecitabine was administered. Treatment response was evaluated in terms of disease down-staging and TRG. Acute toxicity was evaluated according to the CTC-AE 4.0 scale. Results: A total of 76 patients were identified for this analysis. A dose of 45 Gy was prescribed to the entire mesorectum and pelvic lymph nodes with a median SIB dose of 54 Gy (range 52.5-57.5) to the tumor and corresponding mesorectum. Overall, 74/76 (97.4%) patients completed the planned RT, whereas 64/76 (84.2%) patients completed the prescribed CT. Eight (10.5%) patients developed grade 3-4 acute toxicity. Overall, 72/76 patients underwent surgery. The tumor and nodal down-staging was documented in 51 (70.8%) and 43 (67%) patients, respectively. Twenty (27.8%) patients obtained a pathologic complete response. Surgical morbidity was reported in 13/72 patients (18.1%). Conclusions: Although retrospective in design, this study indicates that IMRT-SIB with a dose range of 52.5-57.5 Gy (median 54 Gy) and concomitant Capecitabine appears feasible, well tolerated and effective in terms of disease down-staging and pathological complete response. Long-term toxicity and the impact on disease control and patient survival will be evaluated with a longer follow-up time. Trial r

Published
2017

9. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

Author

Lupattelli, Marco, primary, Matrone, Fabio, additional, Gambacorta, Maria Antonietta, additional, Osti, Mattia, additional, Macchia, Gabriella, additional, Palazzari, Elisa, additional, Nicosia, Luca, additional, Navarria, Federico, additional, Chiloiro, Giuditta, additional, Valentini, Vincenzo, additional, Aristei, Cynthia, additional, and De Paoli, Antonino, additional

Published
2017
Full Text
View/download PDF

11. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients

Author

Fabio Matrone, Maika di Benedetto, Giampaolo Montesi, Gabriella Macchia, Giuditta Chiloiro, Liliana Belgioia, E. Palazzari, R.M. Niespolo, Francesco Romeo Filippone, L. Giaccherini, M.E. Rosetto, Aldo Sainato, Salvatore Parisi, Luciana Caravatta, Antonino De Paoli, Mattia Falchetto Osti, Piera Sciacero, A. Fontana, Vincenzo Valentini, A. Caroli, Carlo Capirci, Caterina Boso, Lucia Turri, Alessio G. Morganti, Maria Antonietta Gambacorta, S. Montrone, Almalina Bacigalupo, Domenico Genovesi, Vincenzo Picardi, Alessandra Galardi, Carlotta Masciocchi, Marco Lupattelli, Giovanna Mantello, Macchia, Gabriella, Gambacorta, Maria Antonietta, Masciocchi, Carlotta, Chiloiro, Giuditta, Mantello, Giovanna, di Benedetto, Maika, Lupattelli, Marco, Palazzari, Elisa, Belgioia, Liliana, Bacigalupo, Almalina, Sainato, Aldo, Montrone, Sabrina, Turri, Lucia, Caroli, Angela, De Paoli, Antonino, Matrone, Fabio, Capirci, Carlo, Montesi, Giampaolo, Niespolo, Rita Marina, Osti, Mattia Falchetto, Caravatta, Luciana, Galardi, Alessandra, Genovesi, Domenico, Rosetto, Maria Elena, Boso, Caterina, Sciacero, Piera, Giaccherini, Lucia, Parisi, Salvatore, Fontana, Antonella, Filippone, Francesco Romeo, Picardi, Vincenzo, Morganti, Alessio Giuseppe, and Valentini, Vincenzo

Subjects
medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Urology, R895-920, 030230 surgery, Article, 03 medical and health sciences, Medical physics. Medical radiology. Nuclear medicine, 0302 clinical medicine, Chemoradiation, Rectal cancer, Surgery, TME, Time interval, Rectal Adenocarcinoma, Medicine, Radiology, Nuclear Medicine and imaging, Stage (cooking), RC254-282, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Chemotherapy, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, medicine.disease, Total mesorectal excision, Radiation therapy, Oncology, 030220 oncology & carcinogenesis, Population study, business
Abstract

Highlights • A large population based analysis to evaluate pathologic response according to time of surgery. • LARC patients were treated with modern techniques of radiotherapy and surgery. • The rate of pCR increased according to time interval from 12.6% to 31.1%. • The pCR increasing was 1.5% (about 0.2%/die) per each week of waiting. • Lengthening the interval (>13 weeks) significantly improved the pathological response., Background To retrospectively evaluate the difference in terms of pathologic complete response (pCR) according to time elapsed between chemoradiation (CRT) and total mesorectal excision (TME) on a large unselected real-life dataset of locally advanced rectal cancer (LARC) patients. Methods A multicentre retrospective cohort study of LARC patients from 21 Italian Radiotherapy Institutions was performed. Patients were stratified into 3 different time intervals from CRT. The 1st group included 300 patients who underwent TME within 6 weeks, the 2nd 1598 patients (TME within 7–12 weeks) and the 3rd 196 patients (TME within 13 or more weeks after CRT), respectively. Results Data on 2094 LARC patients treated between 1997 and 2016 were considered suitable for analysis. Overall, 578 patients had stage II while 1516 had stage III histological proven invasive rectal adenocarcinoma. A CRT schedule of one agent (N = 1585) or 2-drugs (N = 509) was administered. Overall, pCR was 22.3% (N = 468 patients). The proportion of patients achieving pCR with respect to time interval was, as follows: 12.6% (1st group), 23% (2nd group) and 31.1% (3rd group) (p 5040 cGy (p = 0.002) and longer interval (p 13 weeks) from CRT to surgery improves the pathological response (pCR and pathologic partial response; pPR) in comparison to historic data. Furthermore, radiotherapy dose >5040 cGy and two drugs chemotherapy correlated with pPR rate.

Published
2017

12. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response

Author

Fabio Matrone, Marco Forlin, Claudio Belluco, Antonino De Paoli, Angela Buonadonna, Ettore Bidoli, Renato Cannizzaro, G. Bertola, Vincenzo Canzonieri, Matteo Olivieri, Belluco, Claudio, Forlin, Marco, Olivieri, Matteo, Cannizzaro, Renato, Canzonieri, Vincenzo, Buonadonna, Angela, Bidoli, Ettore, Matrone, Fabio, Bertola, Giulio, and De Paoli, Antonino

Subjects
Oncology, Male, Time Factors, Colorectal cancer, medicine.medical_treatment, Endosonography, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy CRT, Medicine, Organ Sparing Treatments, Neoadjuvant therapy, Chemoradiotherapy, Middle Aged, Primary tumor, Magnetic Resonance Imaging, Neoadjuvant Therapy, Survival Rate, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Lymphatic Metastasis, 030211 gastroenterology & hepatology, Female, medicine.medical_specialty, Rectum, Adenocarcinoma, Disease-Free Survival, 03 medical and health sciences, Internal medicine, Humans, Survival rate, Mesorectal, Aged, Neoplasm Staging, Colorectal Cancer, Rectal Neoplasm, business.industry, Rectal Neoplasms, Chemoradiotherapy, Adjuvant, medicine.disease, Surgery, Dose Fractionation, Radiation, Lymph Nodes, business
Abstract

Background Organ preservation strategies are under investigation for patients with locally advanced rectal cancer (LARC) who achieve a complete pathologic response in the primary tumor (ypT0) after neoadjuvant chemoradiation therapy (CRT). This study explored the value of this approach for cN+ patients. Methods Data were retrieved from our institutional prospective rectal cancer database. Tumors with mesorectal lymph nodes larger than 5 mm shown on endorectal ultrasonography, pelvic magnetic resonance imaging, or both were staged as cN+. Results The study population comprised 226 patients (142 men and 84 women; median age, 64 years) with LARC who underwent CRT followed by surgery including total mesorectal excision (TME) (n = 179) and full-thickness local excision (LE) (n = 47) between 1996 and 2013. At staging, 123 patients (54.4 %) were cN+. In 65 cases (28.7 %), ypCR was observed. Metastatic mesorectal lymph nodes (ypN+) were detected in 41.6 % of the cN+ patients and in 2.8 % of the cN0 patients (P

Published
2016

13. Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.

Author

Palumbo I, Matrone F, Montesi G, Bellavita R, Lupattelli M, Saldi S, Frattegiani A, Arena E, Mariucci C, Falcinelli L, Bini V, and Aristei C

Subjects
Aged, Aged, 80 and over, Dose Fractionation, Radiation, Humans, Male, Middle Aged, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms drug therapy, Radiometry, Radiotherapy, Intensity-Modulated methods, Risk Factors, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Prostatic Neoplasms radiotherapy, Radiation Injuries prevention & control, Rectum radiation effects
Abstract

Aim: To analyze risk factors for acute rectal toxicity during hypofractionated intensity-modulated radiotherapy (IMRT) for prostate cancer., Patients and Methods: A total of 195 patients received 74.25 Gy in 33 fractions to the prostate and, if involved, to the seminal vescicles (SV). When the risk of SV involvement was >15% according to the Roach's formula, they received 62 Gy in 33 fractions. Overall, 107/195 patients (54.87%) received hormonal therapy (luteinizing hormone-releasing hormone analogue, anti-androgen, or both). Common Terminology Criteria for Adverse Events version 3.0 was used to classify rectal toxicity., Results: Acute rectal toxicity occurred in 79 (40.51%) patients (grade 1 in 44). In univariate analysis, use of calcium channel blockers significantly reduced the acute rectal toxicity rate and 3-hydroxy-methylglutaryl CoA reductase inhibitors (statins) significantly reduced the rectal toxicity rate and grade. In multivariate analysis, only statin use was an independent protective factor., Conclusion: In patients with prostate cancer treated with a moderate hypofractionated IMRT schedule, use of statins lowered the incidence and grade of acute rectal toxicity., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results